Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep;164(2b):655-66.
doi: 10.1111/j.1476-5381.2011.01388.x.

The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys

Affiliations

The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys

Jennifer L Stewart et al. Br J Pharmacol. 2011 Sep.

Abstract

Background and purpose: The fatty acid amide hydrolase inhibitor URB 597 increases brain anandamide levels, suggesting that URB 597 could enhance the behavioural effects of anandamide. The goal of the current study was to examine and characterize the in vivo pharmacology of URB 597 alone and in combination with anandamide and Δ⁹-tetrahydrocannabinol (Δ⁹ -THC) in two drug discrimination assays in rhesus monkeys.

Experimental approach: The effects of URB 597 alone and in combination with anandamide were investigated in one group of monkeys (n= 4) that discriminated Δ⁹-THC (0.1 mg·kg⁻¹ i.v.) from vehicle, and in another group (n= 5) receiving chronic Δ⁹-THC (1 mg·kg⁻¹ 12 h⁻¹ s.c.) that discriminated the cannabinoid antagonist rimonabant (1 mg·kg⁻¹ i.v.).

Key results: Intravenous anandamide fully substituted for, and had infra-additive effects with, Δ⁹-THC. URB 597 (up to 3.2 mg·kg⁻¹ i.v.) did not substitute for or modify the effects of Δ⁹-THC but markedly increased the potency (32-fold) and duration of action of anandamide. The rimonabant discriminative stimulus in Δ⁹-THC-treated monkeys (i.e. Δ⁹-THC withdrawal) was attenuated by both Δ⁹-THC (at doses larger than 1 mg·kg⁻¹ per 12 h) and anandamide but not by URB 597 (3.2 mg·kg⁻¹). URB 597 did not increase the potency of anandamide to attenuate the rimonabant-discriminative stimulus.

Conclusions and implications: URB 597 enhanced the behavioural effects of anandamide but not other CB₁ agonists. However, URB 597 did not significantly enhance the attenuation of Δ⁹-THC withdrawal induced by anandamide. Collectively, these data suggest that endogenous anandamide in primate brain does not readily mimic the behavioural effects of exogenously administered anandamide.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effects of Δ9-THC and anandamide, alone (top) and in combination (bottom), in monkeys discriminating Δ9-THC (0.1 mg·kg−1 i.v.) from vehicle. Abscissae: vehicle (V) or dose in mg·kg−1 body weight. Ordinates: mean (±SEM) percentage of responding on the Δ9-THC lever. The composite additive line was determined from linear regression of all data from the individual dose–response curves (top panel) expressed as a function of the theoretically derived, combined total dose of Δ9-THC and anandamide (bottom panel, composite additive). The solid line in the bottom panel was determined from linear regression of the experimentally derived data produced by the combination of Δ9-THC and anandamide.
Figure 2
Figure 2
Effects of URB 597, alone and in combination with Δ9-THC (left) or anandamide (right), in monkeys discriminating Δ9-THC (0.1 mg·kg−1 i.v.) from vehicle. Abscissae: vehicle (V) or dose in mg·kg−1 body weight. Ordinates: mean (±SEM) percentage of responding on the Δ9-THC lever (top) and mean (±SEM) response rate expressed as a percentage of control (V training days) rate [Rate (% control)] (bottom).
Figure 3
Figure 3
Time course for anandamide, alone and in combination with URB 597, in monkeys discriminating Δ9-THC (0.1 mg·kg−1 i.v.) from vehicle. Abscissae: time in minutes. Ordinates: mean (±SEM) percentage of responding on the Δ9-THC lever (top) and mean (±SEM) response rate expressed as a percentage of control rate [Rate (% control)] (bottom).
Figure 4
Figure 4
Effects of Δ9-THC (left) and anandamide (right), alone and in combination with rimonabant, in Δ9-THC-treated (1 mg·kg−1 12 h−1 s.c.) monkeys discriminating rimonabant (1 mg·kg−1 i.v.). Abscissae: vehicle (V) or dose in mg·kg−1 body weight of rimonabant. Ordinates: mean (±SEM) percentage of responding on the rimonabant lever (top) and mean (±SEM) response rate expressed as a percentage of control (V training days) rate [Rate (% control)] (bottom).
Figure 5
Figure 5
Effects of URB 597, alone (left) and in combination with anandamide (right), in Δ9-THC-treated (1 mg·kg−1 12 h−1 s.c.) monkeys discriminating rimonabant (1 mg·kg−1 i.v.). Abscissae: vehicle (V) or dose in mg·kg−1 body weight of rimonabant. Ordinates: mean (±SEM) percentage of responding on the rimonabant lever (top) and mean (±SEM) response rate expressed as a percentage of control (V training days) rate [Rate (% control)] (bottom). The dashed and solid lines not connected to symbols are the effects of 10 and 32 mg·kg−1 of anandamide, respectively, in combination with rimonabant, which are re-plotted from Figure 4.
Figure 6
Figure 6
Magnitude of rightward shift in the rimonabant dose-response function expressed as a function of dose of Δ9-THC, anandamide alone and anandamide plus URB 597. Abscissa: dose in mg·kg−1 body weight. Ordinate: mean (±SEM) rightward shift in the rimonabant dose-response function, calculated as rimonabant ED50 following pretreatment with a cannabinoid agonist divided by the control rimonabant ED50.

Similar articles

Cited by

References

    1. Adams IB, Compton DR, Martin BR. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther. 1998;284:1209–1217. - PubMed
    1. Alexander SPH, Mathie A, Peters JA. Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol. 2009;158:S1–S254. - PMC - PubMed
    1. Castelli MP, Paola Piras A, D'Agostino A, Pibiri F, Perra S, Gessa GL, et al. Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2. Eur J Pharmacol. 2007;573:11–19. - PubMed
    1. Childers SR. Activation of G-proteins in brain by endogenous and exogenous cannabinoids. AAPS J. 2006;8:E112–E117. - PMC - PubMed
    1. Chung T, Martin CS, Cornelius JR, Clark DB. Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents. Addiction. 2008;103:787–799. - PMC - PubMed

Publication types